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Abstract: This study reports on L-carnosine phytosomes as an alternative for the prodrug 
N-acetyl-L-carnosine as a novel delivery system to the lens. L-carnosine was loaded into lipid-
based phytosomes and hyaluronic acid (HA)-dispersed phytosomes. L-carnosine-phospholipid 
complexes (PC) of different molar ratios, 1:1 and 1:2, were prepared by the solvent evaporation 
method. These complexes were characterized with thermal and spectral analyses. PC were 
dispersed in either phosphate buffered saline pH 7.4 or HA (0.1% w/v) in phosphate buffered 
saline to form phytosomes PC1:1, PC1:2, and PC1:2 HA, respectively. These phytosomal 
formulations were studied for size, zeta potential, morphology, contact angle, spreading coef-
ficient, viscosity, ex vivo transcorneal permeation, and cytotoxicity using primary human corneal 
cells. L-carnosine-phospholipid formed a complex at a 1:2 molar ratio and phytosomes were 
in the size range of 380–450 nm, polydispersity index of 0.12–0.2. The viscosity of PC1:2 HA 
increased by 2.4 to 5-fold compared with HA solution and PC 1:2, respectively; significantly 
lower surface tension, contact angle, and greater spreading ability for phytosomes were also 
recorded. Ex vivo transcorneal permeation parameters showed significantly controlled corneal 
permeation of L-carnosine with the novel carrier systems without any significant impact on 
primary human corneal cell viability. Ex vivo porcine lenses incubated in high sugar media 
without and with L-carnosine showed concentration-dependent marked inhibition of lens 
brunescence indicative of the potential for delaying changes that underlie cataractogenesis that 
may be linked to diabetic processes.
Keywords: lipoid S 75, phytosomes, L-carnosine, cataract, hyaluronate sodium, ocular 
delivery
Introduction
L-carnosine is a β-alanyl histidine dipeptide and is endogenously present in appreciable 
amounts in skeletal muscles, the human lens, and in relatively lower concentrations 
in other human tissues.1 Its exact physiological function is unknown but, enhancing 
buffering capacity of the cell recovery from muscle fatigue and cell membrane stabili-
zation are the main identifiable metabolic roles ascribed to this dipeptide.1 In addition, 
carnosine is known for its indirect intracellular antioxidant activity that is capable of 
preventing the accumulation of oxidized products derived from lipid peroxidation of 
cell membranes. This effect is more likely to be indirect by potentiating the effect 
of the lipid soluble antioxidant α-tocopherol.1
Recently, other potential therapeutic benefits of L-carnosine have been high-
lighted, notably the slowing of ageing processes and the protection from senile 
cataract formation. L-carnosine has been used in the form of a prodrug (N-acetyl 
carnosine) to enhance its permeation through the cornea. N-acetyl carnosine in turn 
is hydrolyzed by esterase in the aqueous humor to release L-carnosine to the lens.2,3 
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The use of a prodrug might improve corneal permeation; 
some studies have shown promising results for such an 
approach in rabbit and in human eyes.2–4 However, the 
process relies on the activity of ocular esterase, which is 
a protein, and as such might be susceptible to advanced 
glycation with ageing and/or be expressed in lower levels 
as an inevitable consequence of ageing.5,6 Either way, the 
ocular bioavailability of the active form might be adversely 
affected and ultimately might affect the anticataractogenic 
potency. In this study, the potential of adopting a lipid-
based formulation along with a viscosity enhancement 
approach was explored in an attempt to modulate corneal 
permeation of the parent form L-carnosine; this is likely 
to provide an attractive alternative to using the prodrug 
N-acetyl-L-carnosine. 
Phytosomes are innovative lipid carriers; their size is in 
the submicron range and, as the name suggests, the candidate 
drugs are phytopharmaceuticals; ie, of plant origin.7,8 In a 
broader sense, the term phytosomes can be used to describe 
any complex unit that involves a supramolecular association 
between phospholipid and a guest drug molecule of favorable 
physicochemical criteria. For example, mitomycin C is an 
antibiotic anticancer drug derived from bacteria and has been 
recently formulated as a phytosome complex.9 Phytosomes 
can be considered as lipid–drug compatible supramolecular 
complexes; once dispersed in aqueous media, they self-
assemble into vesicular structures similar to liposomes but 
with a different guest localization.9 In liposomes, water 
soluble (WS) drug molecules are trapped in the aqueous 
core or, in the case of multilamellar liposomes, in other 
aqueous compartments; whereas, phytosome drug molecules 
are favorably aligned electrostatically and hydrogen-bound 
with the phospholipid polar head groups (negatively charged 
phosphate and positively charged ammonium of the choline 
moiety). The main advantages of phytosomes are their higher 
drug-to-carrier load compared with liposomes, that they 
can be easily stored in a solid/lyophilized form ready for 
reconstitution,8 and their smaller size and biocompatibility 
which renders them more attractive carriers for hydrophilic 
drug molecules. Unlike liposomes, not all WS drugs can be 
loaded into phytosomes. The candidate drug should have a 
certain polarity and adequate functional groups (eg, COOH, 
OH, NH2, -NH- or =NH) that can serve as a platform for 
electrostatic interactions and hydrogen-bonding with phos-
pholipid polar head groups.9
Hyaluronic acid (HA), also called hyaluronan and 
hyaluronate sodium, is a negatively charged hydrophilic 
polysaccharide that is naturally distributed throughout 
connective tissues, epithelia, synovial fluid in the joints 
and neural tissues as well as in the vitreous of the eye.10 
HA is composed of repeated units of D-glucuronic acid and 
N-acetyl-D-glucosamine moieties10 and has gained increas-
ing popularity in drug delivery, medical, and pharmaceutical 
applications.11 HA hydrogels of concentrations up to 2% w/v 
have been utilized for their mucoadhesive properties.12 
Gel-cored liposomes or liposomes entrapping a hydrogel 
polymer such as HA are advanced as an innovative approach 
in drug delivery, and liposome integrity and stability have 
been reported to be enhanced in HA gels with more sustained 
drug release characteristics.13 These promising liposomes are 
hybrids of lipid vesicles and hydrogels and have been found 
to be versatile and promising.13,14
HA has been used widely in ophthalmology and HA of 
relatively low concentrations between 0.1% w/v and 0.3% w/v 
is commercially available for symptomatic relief of dry 
eye conditions and for promoting healing after cataract and 
other refractive surgeries.15,16 HA can slow tear evaporation, 
restore precorneal tear film stability at the ocular surface, 
and relieve discomfort due to dry eye. Dry eye could be an 
ocular manifestation of certain systemic conditions, and it 
has been linked to age-related cataractogenesis.17 This study 
aimed at investigating L-carnosine as a potential alternative 
to its prodrug N-acetyl carnosine by adopting a novel lipid-
based formulation approach. Specific objectives were the 
preparation, characterization, and evaluation of phytosomes 
and phytosome-HA systems to establish their potential as 
promising ocular carriers of L-carnosine. 
Materials and methods
Materials
L-carnosine, cellophane membrane (molecular weight cutoff 
12,000–14,000 Da), nitro blue tetrazolium (NBT), and MTT 
were purchased from Sigma-Aldrich Co. (St Louis, MO, 
USA). HA was purchased from Acros Organics, (Thermo 
Fisher Scientific, Waltham, MA, USA). Ammonium molyb-
date was purchased from Hopkin & Williams Ltd, Chadwell 
Heath, England. Lipoid s 75 was donated by Lipoid GmbH, 
Ludwigshafen, Germany. All other chemicals and reagents 
were of analytical grade and used as received.
Preparation of l-carnosine–phospholipid 
complex
L-carnosine and lipoid s 75 in molar ratios of 1:1 and 1:2, 
were separately dissolved in MilliQ (deionized) water 
(10 mL) and methanol (30 mL) respectively, mixed in a 
100 mL round bottom flask and refluxed for 1 hour at 40°C. 
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The solvent was removed by rotary evaporation in a Buchi 
rotary evaporator (Buchi, Flawil, Switzerland).8 The prepared 
phospholipid complexes (PC) were transferred into sealed 
glass vials and stored at ambient conditions (15°C±5°C) for 
further use.
characterization of the prepared 
l-carnosine-Pc
Differential scanning calorimetry 
Samples of L-carnosine powder, Lipoid S 75, PC of 1:1 and 
1:2 mol/mol ratios were weighed (typically 5–8 mg) sepa-
rately in an aluminum pan, covered with an aluminum lid 
and hermitically sealed using a pan press. The temperature 
of the pan was gradually increased from 25°C to 300°C at 
a rate of 10°C/min using a differential scanning calorimeter 
(Mettler Toledo Differential scanning calorimetry [DSC] 
822e0, Greifensee, Switzerland) pre-calibrated with indium. 
The purging gas was nitrogen at a flow rate of 45 mL/min. 
Data were collected online using Mettler STARe software 
version 8.10.
Fourier transform-infrared spectroscopy 
The Fourier transform-infrared (FT-IR) spectra for L-carnos-
ine, Lipoid S 75, PC1:1 and PC1:2 were recorded using an 
FT-IR spectrometer (Thermo Scientific Nicolet is5, Thermo 
Fisher Scientific). A clean diamond window was used to mea-
sure the background spectrum. A sufficient amount (approxi-
mately 2–4 mg) of the sample was placed to form a thin film 
covering the diamond window. The data were acquired and 
analyzed using Omnic software (Omnic version 8.2, Thermo 
Fisher Scientific). The FT-IR spectra were recorded at spectral 
resolution of 2 cm-1 with an average of 20 scans.
X-ray diffraction studies
The X-ray diffraction (XRD) analysis of L-carnosine, Lipoid 
s 75, PC1:1, and PC1:2 was performed using an X-ray dif-
fractometer (Bruker AXS D8 Advance; Bruker Corpora-
tion, Billerica, MA, USA). The X-ray diffractograms were 
scanned at 40 kV tube voltage at room temperature and the 
scanning diffraction angle (2θ) ranged from 2° to 45° with a 
step size of 0.1°. The data were collected online using soft-
ware DIFFRAC plus XRD commander version 2.3 (Bruker 
Corporation).
Preparation of l-carnosine–phospholipid 
dispersions
Specified amounts of the prepared solid formulations PC1:1 
(500 mg) and PC1:2 (900 mg) equivalent to 1% w/v of 
L-carnosine were dispersed in 10 mL of phosphate buffered 
saline (PBS) warmed to 40°C and vortexed for 5 minutes to 
form phytosomal dispersions. An additional batch of PC1:2 
was dispersed in PBS containing 0.1% w/v HA and labeled 
PC1:2 HA. Free L-carnosine molecules were separated from 
those in complex with phytosomal vesicles by extensive 
dialysis through a cellulose membrane of molecular weight 
cutoff 1,200–14,000 Da. Samples (2 mL each) of the pre-
pared phytosomes were transferred into a dialysis bag and 
subjected to extensive dialysis for 2 hours (100 mL of PBS 
each) at 4°C. The encapsulation efficiency was estimated as 
described elsewhere.18,19 
characterization of l-carnosine-
phospholipid dispersions
Particle size and zeta potential measurements 
The particle size, polydispersity index (PDI), and zeta 
potential of PC1:1, PC1:2, and PC1:2 HA were analyzed 
(after a suitable dilution of 1:30 with PBS) by dynamic light 
scattering using a Malvern Zetasizer 3000HSA (Malvern 
Instruments, Malvern, UK) at 25°C. Zeta potential was 
measured by laser Doppler electrophoresis using the same 
instrument under the same conditions. Size values were 
reported as mean hydrodynamic diameter. All measurements 
were done in triplicate.
Transmission electron microscopy
Imaging of selected PC formulations was performed using 
the transmission electron microscope (JEM 1010, JEOL, 
Tokyo, Japan) with an acceleration voltage of 80 kV. Samples 
were diluted with PBS (1:30). A drop of the diluted sample 
was placed on a carbon-coated copper grid and allowed to 
leave a thin film on the grid before being stained by adding 
one drop of a solution of 2% w/v ammonium molybdate 
in ammonium acetate buffer (2%). The stained films were 
imaged and photographed using JEOL software.
Contact angle, surface tension, spreading coefficient, 
and viscosity measurements
Contact angle (θ) measurements were performed using a drop 
shape analyzer (goniometer) (Kruss Drop Shape Analysis, 
Hamburg, Germany). A Hamilton syringe was filled with 
each of the tested phytosomal formulations. Approximately 
20 µL of each formulation was dropped onto a glass slide 
at ambient conditions. The image of the drop was captured 
and measured by Kruss software. The measurements were 
performed in triplicate and results were presented as mean 
values ± standard deviation.
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The tendency for spreading can be quantified in terms of 
the spreading coefficient (S) using Equation 1.20 
 S = γ
L/A 
(cos θ - 1) (1)
where γ
L/A
 is the surface tension of the liquid. If θ is larger 
than 0°, the term (COS θ - 1) and the value of S will be nega-
tive. The condition for complete or spontaneous wetting is 
thus a zero value for the contact angle. The surface tension 
(γ) values of carnosine solution and the prepared phytosomes 
(PC1:1 and PC1:2) were determined at ambient conditions 
using an interfacial tensiometer (Kibron, Inc., Helsinki, 
Finland). Data were collected online using Aqua PI plus 
software (Kibron, Inc., Helsinki, Finland). All measurements 
were performed in triplicate.
The viscosity of the prepared drug solution and formula-
tions was studied using a Brookfield viscometer (Brookfield 
DV-II+Pro; Brookfield AMETEK, Middleboro, MA, USA) 
equipped with an S62 spindle. The measurements were 
performed at 25°C.
ex vivo permeation studies using excised 
porcine eyes
Enucleated porcine eyes were carefully examined for any cor-
neal damage, such as epithelial scarring, corneal opacity, and 
corneal vascularization, before the cornea was dissected. The 
dissection was performed with extreme care to avoid touching 
the surface of the cornea. A small ring of scleral tissue was left 
around the cornea. The scleral tissue served as a gasket and 
the cornea was mounted with endothelium facing the receptor 
compartment and epithelium facing the donor compartment. 
Franz-diffusion cells were used for ex vivo permeation 
studies, and the temperature was kept at 35°C±0.5°C. The 
receptor chambers were filled (12 mL) with a PBS (pH 7.4) 
solution supplemented with 2.4 mM glucose. The medium 
was constantly stirred using small magnetic bars. A sample 
(2 mL) of each formulation was transferred into the donor 
compartment providing surface area of 1.7 cm2. Samples 
(0.4 mL) were withdrawn at predetermined time points for up 
to 8 hours and replaced with the same volume of the receptor 
medium without drug. The samples were analyzed using an 
in-house developed high performance liquid chromatography 
method. The method was developed and validated according 
to International Conference on Harmonization guidelines and 
has been recently published.19 In brief, the high performance 
liquid chromatography system (Shimadzu LC-2010AHT, 
Shimadzu Corporation, Kyoto, Japan) comprised a quater-
nary pump, an automatic sampler and a UV detector with 
data acquisition by Lab solutions software version 5.42 SP5 
(Shimadzu Corporation). The chromatographic separation 
was achieved using a Supelcosil C18 column (5 µm; 250×4.6 
mm, Supelco Inc, Sigma-Aldrich Co., St Louis, MO, USA) 
maintained at 40°C. The mobile phase was composed of 0.1% 
v/v trifluoroacetic acid pH 2.5 (98% v/v) and acetonitrile 
(2% v/v). The isocratic flow rate was 1.0 mL/min and the 
injection volume was fixed at 30 µL. Detection was carried 
out at a wavelength of 220 nm. 
ex vivo permeation data analysis 
The apparent permeability coefficient (P
app
, cm/s) was cal-
culated using Equation 2.21
 
P
Q
t ACapp
o
= ∆
∆ ( )3600
 
(2)
where ∆Q/∆t is the permeability rate of L-carnosine across 
the excised porcine cornea and it was equal to the gradient 
of the L-carnosine permeated (Q) versus time (t) curve; C
o
 
is the initial drug concentration (µg/cm3); A is the corneal 
surface area (cm2). The lag time was determined graphically 
by extrapolating the steady-state line to the time axis.
cytotoxicity evaluation of phytosomes (MTT assay)
Primary human corneal epithelial cells (ATCC pcs-700-
010) from American Type Culture Collection, (Manassas, 
VA, USA) were prepared and seeded out at approximately 
2×104 cells/well into 96-well plates (Nunc, Sigma-Aldrich 
Co.) in Corneal Epithelial Cell Basal Medium containing 
the following supplements (LGC standards): apo-transferrin 
(5 mg/mL), epinephrine (1.0 mM) extract P (0.4%), hydrocor-
tisone hemisuccinate (100 ng/mL), L-glutamine (6 mM), rh 
insulin (5 mg/mL), and CE growth factor (1 mL, proprietary 
formulation). Cells were allowed to establish for 48 hours 
prior to treatment in the 96-well culture plate. Media were 
subsequently removed and fresh media containing treatments 
(eight wells used per condition) added. The treatments were 
as follows: plain carriers of a concentration of 8% equivalent 
to the amount of lipid in PC1:2 formulation and half carrier 
concentration (4% w/v); L-carnosine solution of 1% w/v and 
half the drug solution (0.5% w/v); PC1:2 and half PC1:2 and 
PC1:2 HA. The medium was used as a negative control and 
benzalkonium chloride (BKC) at a concentration of 0.01% w/v 
was used as a positive control. After 24 hours of treatment, the 
media were removed and the cells washed twice with 37°C 
sterile PBS. The cells were then incubated with 200 µL per 
well of 0.5 mg/mL MTT solution in 37°C Corneal Epithelial 
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Cell Basal Medium (LGC standards). After incubation, the 
MTT solution was carefully removed and the wells washed 
twice with sterile PBS. Finally, 200 µL of dimethyl sulfoxide 
was added to each well to lyse the cells. The cells were gently 
agitated to mix the samples and analyzed on a TECAN Infinite 
M200 pro plate reader (Männedorf, Switzerland) at a wave-
length of 540 nm. Experiments were performed in triplicate.
Incubation of porcine lenses in high sugar media 
with and without l-carnosine 
Excised porcine eyes were collected fresh from a local abattoir. 
Each eye was dissected from the posterior segment to extract 
the whole lens. Lens was rinsed in the medium M199 supple-
mented with 8% fetal bovine serum and antibiotics (penicillin/
streptomycin, 100 units/mL) and then transferred onto a six-well 
plate (Nunclon™ Delta Syrface, Roskilde, Denmark) containing 
10 mL of the medium and incubated for 12 hours at 35°C/5% 
CO
2
.22 Any lens that showed any sign of opacity due to poor dis-
section was discarded. The incubated lenses were divided into 
four groups: a negative control (the lenses were incubated in the 
culture medium without galactose), positive controls (the lenses 
were incubated in a medium containing 30 mM galactose), and 
two treated groups containing 30 mM of galactose and 10 mM 
or 20 mM of L-carnosine and incubated at 35°C/5% CO
2
. The 
media were changed daily for 3 days. Opacity of the lenses was 
evaluated visually on a grid. Whole lenses were homogenized 
in a flacon tube with 8 mL of Tris–HCl buffer pH 8.4 contain-
ing 0.02% sodium azide. The homogenate was centrifuged at 
10,000 rpm for 30 minutes at 4°C. The supernatant was collected 
to obtain WS fraction of lens crystallins.23
NBT assay 
This assay is based on the reducing properties of the advanced 
glycation end products or manifesting as conversion of fruc-
tosamine to NBT to formazan (purple color) under alkaline 
conditions.24,25 An aliquot of 100 µL of WS fractions was 
added to 1 mL of NBT (0.3 M in carbonate buffer pH 10.35). 
The mixtures were incubated at 37°C for 10 minutes, allowed 
to cool down to room temperature, and measured spectro-
photometrically at 530 nm. Percentage glycated crystallins 
was estimated using Equation 3:
 
% glycated crystallins
OD OD
OD
s c
c
=
−
*100
 
(3)
where OD
s
 is the optical density of the positive control or 
treated samples and OD
c
 is the optical density of the nega-
tive control.
statistical analysis
Statistical analysis was performed with Graph Pad Prism 6 
(GraphPad Software, Inc., La Jolla, CA, USA), using analysis 
of variance with a Dunnett post hoc test for confidence inter-
vals of 95% with statistical significance set at P,0.05.
Results and discussion
Dsc studies
The DSC studies were carried out to investigate the crys-
tallinity of L-carnosine and the possibility of formation of 
L-carnosine-phospholipid solid complexes that can be the 
base for formation of phytosomes after dispersion in the 
aqueous media. Figure 1 shows the thermal behaviors of 
L-carnosine, lipoid s 75, PC1:1, and PC1:2. The upper trace 
shows a sharp and strong endothermic peak at 268°C that 
is caused by L-carnosine melting. Lipoid S 75 did not show 
any thermal events in the range of 40°C–300°C as a result 
of its low melting point. For PC1:1, the appearance of a 
broad endothermic peak at 250°C could be ascribed to the 
residual L-carnosine crystallites and appearance of a new 
peak at 114°C was likely to have been caused by forma-
tion of a new complex between the dipeptide drug and the 
phosphatidylcholine of Lipoid S 75. Complete disappear-
ance of the L-carnosine melting peak and appearance of a 
new endothermic peak at 114°C indicate the formation of 
a new complex. The latter thermal event of PC1:2 can be 
ascribed to potential electrostatic interactions and hydrogen 
bonding between the dipeptide drug and phosphatidylcholine. 
Similar results were reported with the phospholipid complex 
of diosmin. A ratio of diosmin:phospholipid at 1:2 mol/mol 
showed complete disappearance of diosmin melting peak 
(291.5°C) and appearance of a new melting peak at 160°C 
suggestive of a complex formation.8 
The drug-HA compatibility studies were performed in an 
attempt to show any possible physiochemical interactions of 
the polysaccharide carrier HA with the drug. The thermo-
grams of L-carnosine did not show any obvious changes in 
the melting points (Figure 1); this indicates that there are no 
physicochemical interactions between L-carnosine and HA 
that might alter or disrupt L-carnosine PC after dispersion.
FT-Ir spectroscopy
FT-IR spectroscopy was employed to further understand 
the potential interactions between L-carnosine and phos-
phatidylcholine (the major constituent in Lipoid S 750), 
as shown in Figure 2. Characteristic IR vibrational peaks 
in the high-frequency region included stretching vibration 
at 3,237 cm-1 and 3,049 cm-1 for the amide hydrogen and 
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Figure 1 Dsc thermograms for l-carnosine, lipoid s 75, Pc1:1, Pc1:2, ha (A), and l-carnosine:ha 1:1 (B).
Abbreviations: Dsc, differential scanning calorimetry; Pc, phospholipid complexes; ha, hyaluronic acid.
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Figure 2 FT-Ir spectra for l-carnosine, lipoid s 75, and Pc1:1 (left trace) and Pc1:2 (right trace).
Abbreviations: FT-Ir, Fourier transform-infrared; Pc, phospholipid complexes.
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of hydrocarbon chains in a smectic liquid crystalline state 
of Lipoid S 75. For PC1:1 and 1:2, the main characteristic 
peaks of L-carnosine appeared at diffraction angles of 20, 
22.8, and 25 2θ. These characteristic peaks were detected at 
low, broader, and decreasing intensities, which are indica-
tive of residual crystallites of L-carnosine. The DSC results 
and appearance of a single peak at much lower intensity 
compared with the pure drug suggest a complex formation 
at 1:2 molar ratio and the complex melting peak is at a tem-
perature of 112°C.
size and zeta potential measurements
Table 1 shows that the prepared complexes, when dis-
persed in aqueous medium (PBS) and in PBS containing 
HA (0.1% w/v), can self-assemble into phytosomes with a 
size range of 380–450 nm and narrow size distributions, as 
shown from PDI values, and high negative zeta potential 
values. These dipeptide-PC are negatively charged because 
of the high electron density generated by the fully ionized 
phosphate groups of the phospholipids within the neutral 
pH medium of the PBS.9 PC1:1 demonstrated a significantly 
larger average size (450 nm), compared with PC1:2 (385 nm) 
and PC1:2 HA (380 nm). This can be attributed to the fact 
that PC1:1 is an incomplete complex with free L-carnosine 
molecules and free negatively charged head groups of 
phospholipids that can self-assemble into phytosomes of a 
relatively larger hydrodynamic radius, mainly due to elec-
trostatic repulsion. However, PC1:2 is a complete complex 
and the polar head groups of the phospholipids were partially 
neutralized and therefore could self-assemble into smaller 
sized L-carnosine phytosomes. It is worth noting that dis-
persion of phytosomes in HA had no significant impact on 
sizes of L-carnosine phytosomes. However, addition of HA 
reduced the PDI and it may be that increasing the viscosity 
of the dispersion medium reduced the tendency of vesicles 
to aggregate. PC1:2 already has a high zeta potential value 
and is equally well dispersed in either PBS or PBS contain-
ing HA (0.1% w/v). Similar results were also reported with 
the entrapment efficiency (EE%). PC1:2 vesicles showed a 
marked increase in EE% (85%) compared with that estimated 
for PC1:1 (55%). This 1.5-fold increase in the EE% for 
phytosomes PC1:2 can be attributed to the vesicles having 
sufficient PC molecules to self-assemble into phytosomes, 
and as a result more L-carnosine molecules become favorably 
entrapped in the phytosomes rather than in bulk solution. 
Addition of HA (viscosity enhancing agent) resulted in a 
slight improvement of EE% (90%) for PC1:2 HA, compared 
with 85% for PC1:2. A slight increase in the viscosity is likely 
? ?? ?? ?? ?? ??
???????????
???????????
?????
?????
?θ
Figure 3 X-ray diffractograms of l-carnosine, lipoid s 75, and phytosomal complexes 
(Pc1:1 and Pc1:2).
Abbreviation: Pc, phospholipid complexes.
protonated terminal amine (NH
3
)+ of the free L-carnosine.26 
Other important peaks were at 2,162 cm-1 and 1,643 cm-1 
due to vibrational bending of imidazole (N–H) and amide 
group stretching respectively.26
For Lipoid S 75, strong absorption peaks assigned at 
2,922 cm-1 and 2,852 cm-1 were the result of antisymmetric 
and symmetric stretching of acyl chains (CH
2
), respectively. 
Another strong absorption peak at 1,738 was caused by ester 
carbonyl (C=O) group stretching.27 All these characteristic 
peaks and their characteristic wavenumbers were recorded for 
PC1:1, indicating no detectable interactions at 1:1 ratio. While 
these bands were distinctly representative of L-carnosine, 
their disappearance in the case of PC1:2 could be attributed 
to the shielding effect of lipoid s 75, hydrogen bonding, and 
formation of L-carnosine phosphatidylcholine complex. 
Appearance of a broad strong absorption peak at 3,371 cm-1 
was due to H-bond formation of the amide (–CONH–) with 
phosphate groups of lipoid s 75 and disappearance of the 
characteristic L-carnosine peak at 2,162 cm-1.
XrD studies 
Figure 3 shows the XR diffractograms for L-carnosine, lipoid 
s 75, PC1:1, and PC1:2. The L-carnosine showed sharp XRD 
peaks that are typical of a highly crystalline drug. Lipoid 
S 75 showed an intense diffraction peak only at 3 2θ and 
the intermolecular spacing was found to be 31.47Ȧ. This 
can be attributed to an intermolecular space between a stack 
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to enhance EE% due to improving L-carnosine complexation 
with PC molecules.
Transmission electron microscopy
Transmission electron microscopy (TEM) was employed 
to study the size and the shape of the dispersed phytosomes 
PC1:2. Figure 4 shows a representative TEM micrograph 
for PC1:2; the left frame shows the dispersed spheres in a 
matrix of recrystallized PBS salts, while the right frame is a 
magnification of the dispersed system showing characteristic 
spherical structures (PC1:2 phytosomes) with a diameter com-
parable to that measured using dynamic light scattering.
contact angle, surface tension, and 
spreading coefficient measurements
Table 1 shows the surface tension (γ) measurements for the 
prepared phytosomes compared with L-carnosine aqueous 
solution in PBS. The γ values measured for the prepared phy-
tosomes were 42.5, 43, and 45 mN/m. These results revealed 
γ values for the prepared phytosomes that were significantly 
lower than those for the aqueous solution (76 mN/m) 
(P,0.001). However, there was no significant difference 
amongst the γ values measured for the prepared phytosomes 
(P.0.05). 
It is well established that the lower the surface tension, the 
easier it is for the formulations to wet the hydrophobic surface 
of the corneal epithelium.28,29 These values for the tested 
L-carnosine phytosomes were approximately equal to that of 
the average surface tension of the tear fluid (43.6±2.7 mN/m) 
of human eyes.30 This is likely to allow the carriers to mix 
uniformly with greater miscibility and minimal disturbance to 
the precorneal tear film, compared with the drug solution in 
PBS which has a relatively higher surface tension (76 mN/m). 
The lower the surface tension of the ocular formulation, the 
less likely it is to disturb the precorneal tear film and induce 
irritation due to excessive tear evaporation; the negative 
correlation between surface tension and tear break up time 
has been previously reported.30,31 
Table 1 shows the contact angle (θ) and the spreading 
coefficient (S) measurements of the prepared formulations 
compared with the plain vehicle (PBS). 
The θ values of all tested phytosomes in PBS (38° and 42°) 
were significantly lower (P,0.05) than those of the aqueous 
vehicle (50°) and PC1:2 HA (62°). Additionally, the S values 
of the prepared formulations were up to 1.5 to 4 times greater 
than those of the aqueous vehicle. These results suggest 
that spreading of phytosomes on the solid surface is more 
energetically favored and that the prepared formulations 
have better wetting properties than does the aqueous vehicle. 
Hence, the prepared formulations could more promptly and 
easily wet, spread, and adhere to the hydrophobic surface 
of the cornea than an aqueous drug solution. The relatively 
lower spreading ability of PC1:2 HA compared with PC1:2 
is likely to be due to the relatively high viscosity of HA 
Table 1 Size, PDI, entrapment efficiency (EE%), zeta potential, contact angle, surface tension, and spreading coefficient (S) measurements 
of l-carnosine solution compared with phytosomes
Formulation Size (nm) PDI EE% (w/v) Zeta potential (mV) Contact angle (θ °) Surface tension (mN/m) S (mN/m)
l-carnosine* – – – – 50±2.0 76±0.5 -38±1.0
Pc1:1 450±26 0.2 55%±3.5% -48±7.5 38±1.8 42.5±0.8 -9.0±0.5
Pc1:2 385±11 0.15 85%±4% -56±11 42±2.0 43±1.0 -11±0.5
Pc1:2 ha 380±15 0.12 90%±6% -58±9.5 62±2.5 45±2.0 -25±0.7
Note: *L-carnosine solution of 1% w/w was prepared in PBS. The dash indicates that no data was available.
Abbreviations: PDI, polydispersity index; Pc, phospholipid complexes; ha, hyaluronic acid; PBs, phosphate buffered saline.
Figure 4 representative TeM micrograph of Pc1:2 phytosomes.
Abbreviations: TeM, transmission electron microscopy; Pc, phospholipid complexes.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
5.
16
.1
3.
60
 o
n 
17
-J
an
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2823
Phytosome-hyaluronic acid systems for ocular delivery of l-carnosine
hydrogel. The greater viscosity of PC1:2 HA compared to 
PC1:2 means that the former can retain the L-carnosine in 
contact with ocular surface longer than the latter, which 
compensates somewhat for the relatively lower spreading 
ability of PC1:2 HA.
Figure 5 shows the viscosity values of drug solution and 
the prepared formulations at 25°C. The viscosity values for 
the prepared phytosomes and HA were significantly higher 
(P,0.01) than the drug in the aqueous vehicle. The viscos-
ity range was found to be 3 to 12 times higher than that for 
the aqueous vehicle at 25°C. The highest value for PC1:2 
HA was 35 mPa.s, compared to values for HA and PC1:2 
of 15 and 7 mPa.s, respectively. This significant increase 
(P,0.01) could be attributed to the ability of phytosomes 
to strengthen the network formed by HA caused by interac-
tions of phospholipids with D-glucuronic acid and N-acetyl-
D-glucosamine chains. Similar results were reported with 
liposomes dispersed in HA hydrogels, where the elasticity 
and viscosity of HA hydrogel were markedly enhanced in 
the presence of liposome dispersions.13
It has been reported that an increase in the viscosity 
range over 1 to 12.5 mPa.s using methylcellulose as a vis-
cosity imparting agent resulted in a threefold decrease in the 
precorneal drainage rate. This decrease in the drainage rate 
increased the concentration of drug in the precorneal tear 
film.32 In addition, Isopto® and Liquifilm® are widely used 
commercial viscous vehicles for enhancing the ocular bio-
availability of some drugs formulated in simple eye drops. 
These viscous vehicles consist of 0.5% hydroxypropyl methyl-
cellulose and 1.4% polyvinyl alcohol. The viscosity ranges for 
these products are 10–30 mPa.s and 4–6 mPa.s, respectively, 
and both have the convenience of being an eye drop.33 These 
findings indicate that the prepared phytosomes have favorable 
viscosity ranges for prolonged precorneal retention and are 
indeed in line with currently marketed products. 
ex vivo permeation study
Transcorneal permeation profiles of L-carnosine from drug 
solution and different phytosomal formulations through 
excised porcine cornea are shown in Figure 6. Table 2 shows 
transcorneal permeation parameters of L-carnosine from 
the investigated formulations. The following transcorneal 
permeation parameters were calculated: steady-state flux, 
apparent permeability coefficient (P
app
), and lag time (t
L
) 
(Table 2). The prepared phytosomes achieved controlled 
L-carnosine permeation through the corneal tissue compared 
with L-carnosine solution. The steady-state flux and P
app
 
calculated for L-carnosine solution were 2.4 to 5.6 times faster 
than those for PC1:2 and PC1:2 HA, respectively. While the 
drug solution showed better permeation rates compared with 
the prepared PC and PC HA systems on the static receptor 
compartment of the Franz diffusion model used in this study, 
there is an ample body of research to suggest that this pattern 
can be reversed in vivo.34–36 L-carnosine took longer time to 
dissociate from and/or partition through phytosomes bilayer 
membranes, and further time to diffuse through HA matrix 
from PC 1:2 and PC 1:2 HA, respectively. Similar results were 
reported for lipid-based delivery systems, such as liposomes, 
??
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??
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??
?
? ???????????????????
????
????
????
????
?
????? ?? ????????
Figure 5 Viscosity values of L-carnosine solution (1% w/v) compared with HA and 
phytosomes (Pc1:2 and Pc1:2 ha).
Note: results are expressed as mean values ± sD, n=3.
Abbreviations: Pc, phospholipid complexes; ha, hyaluronic acid; sD, standard 
deviation.
?????
?????
?????
?????
?????
?????
???
? ? ? ? ??? ?????????
???
????
????
???
???
????
?
?
????????????? ?????????????????????????
Figure 6 Transcorneal permeation profiles of L-carnosine form drug solution and 
from different phytosomal formulations. 
Note: results are expressed as mean values ± sD, n=3.
Abbreviations: Pc, phospholipid complexes; ha, hyaluronic acid; sD, standard 
deviation.
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niosomes, and solid lipid nanoparticles, using excised rabbit, 
excised bovine, and bioengineered human corneal samples.34–36 
The permeation rate and apparent permeability coefficient 
for acyclovir-encapsulated liposomes and timolol maleate 
(TM)-loaded solid lipid nanoparticles were more controlled 
compared with those of the corresponding drug solutions. 
When these acyclovir liposomes, which demonstrated lower 
permeability, were applied to rabbit eyes, higher ocular bio-
availability for acyclovir was obtained, compared with that for 
the aqueous drug solution.34 More recently, similar results were 
also reported with niosomes; the hypotensive effects of topi-
cally instilled TM into rabbit eyes were significantly greater 
with TM niosomes compared with that from TM solution.37
This is attributed to the ability of lipid-based vesicles 
(liposomes, niosomes, and most likely phytosomes) to pro-
vide longer precorneal residence time and less precorneal 
drug loss than the aqueous solution because of tear dilution 
and spillage. Furthermore, phytosomes can spread more 
evenly on the lipophilic corneal membrane as they have 
better spreading ability and a significantly lower contact 
angle and favorable viscosity (Table 1 and Figure 5). More 
interestingly, the ability of L-carnosine to form a complex 
with PC is more likely to improve the loading capacity of 
phytosomes as a carrier for the WS cargo (L-carnosine) 
compared with conventional liposomes. Figure 7 postulates 
how L-carnosine-PC can self-assemble into phytosomes in 
Table 2 Steady-state flux, apparent permeability coefficient (Papp), lag time, and regression coefficient of L-carnosine
Formulation Steady-state flux (µg/h) Papp ×10-6 (cm/s) Lag time (min) Regression coefficient (R
2)
l-carnosine* 390±32 9.0±0.2 20±4.2 0.995
Pc1:1 250±26 7.0±0.1 15±3.0 0.987
Pc1:2 200±15 4.5±0.1 10±2.8 0.996
Pc1:2 ha 70±4.0 0.8±0.2 29±0.5 0.998
Note: *L-carnosine solution of 1% w/w was prepared in PBS.
Abbreviations: Pc, phospholipid complexes; min, minutes; ha, hyaluronic acid; PBs, phosphate buffered saline.
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Figure 7 graphical representation of self-assembly of l-carnosine phytosomes and drug delivery to the lens. 
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aqueous medium and potentially overcome the outer-coat bar-
rier (cornea) into the anterior chamber and then to the lens. 
cytotoxicity evaluation (MTT assay) of 
phytosomes to primary human corneal 
cells 
Table 3 shows estimated cell viability after a 24-hour exposure 
to different treatments. The positive control (BKC) has been 
shown to be cytotoxic at the duration tested in this study.38–40 
While there were slight decreases in cell viability after expo-
sure to the different formulations and L-carnosine solution, 
these were not statistically significant compared to the nega-
tive control (P.0.05). It is worth noting that BKC (which 
for durations comparable to this study is cytotoxic) is used 
routinely as a preservative in too many commercially avail-
able eye drops at a concentration of 0.01% w/v; the duration 
of exposure of BKC to the eye when applied in eye drops is 
considerably shorter. These findings indicate that phytosomes 
in the concentrations and for the durations tested do not dem-
onstrate cytotoxicity in primary human epithelial cells. 
lens incubation in high sugar media 
Induction of experimental cataract is an important approach 
used to gain a better understanding of cataract formation and to 
help develop potential therapeutic treatments that could delay 
or reverse cataractogenesis. Galactose was used in this study 
to induce cataract formation in vitro in excised porcine lenses. 
On day 3, harvested lenses from negative and positive controls 
and treated groups were placed on a grid to investigate optical 
quality. Lenses, incubated in a high galactose medium, showed 
marked yellowing/browning of lens cortex, compared with con-
trol lenses incubated in a medium free of galactose. This char-
acteristic lens “brunescence” is a consequence of glycation and 
is likely to mimic the processes that underlie diabetic cataract. 
Lens brunescence was partially inhibited by supplementing the 
media with 10 mM L-carnosine, those incubated with 20 mM 
L-carnosine demonstrated lens clarity and lack of brunescence 
comparable to the negative controls (Figure 8). 
The percentage of lens protein glycation recorded in the 
positive control was at least 30%, whereas treatment with 
Table 3 Primary human corneal epithelial cell viability (%) after 
24-hour exposure to the test substances employing MTT assay
Formulation Cell 
viability (%)
Statistical significance 
to the medium
Media (negative control) 100
BKc (positive control) 18±0.63 P,0.05
PC alone (8%) 78±15 P.0.05
PC alone (4%) 92±24 P.0.05
L-carnosine (1%) 76±13.5 P.0.05
L-carnosine (0.5%) 85±19.5 P.0.05
Pc1:2 69±12 P.0.05
half Pc1:2 80.5±11 P.0.05
Pc1:2 ha 77±6 P.0.05
Abbreviations: BKc, benzalkonium chloride; Pc, phospholipid complexes; ha, 
hyaluronic acid.
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Figure 8 Porcine lenses incubated in negative control medium, in high galactose medium, in high galactose with 10 mM l-carnosine, and high galactose with 20 mM 
l-carnosine (A); percentage glycated proteins (B).
Abbreviation: NBT, nitro blue tetrazolium.
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L-carnosine showed a significant inhibition (P,0.05) in the 
percentage of glycated proteins (Figure 8).
Conclusion
This study highlighted that formulating L-carnosine utilizing 
novel lipid-based carriers is a feasible approach. Combining 
HA hydrogel and lipid-based phytosomes using a simple and 
scalable preparation method has shown favorable rheological 
characteristics, spreading ability, sustained drug permeation, 
and tolerability characteristics for potential ocular delivery 
of L-carnosine. L-carnosine showed significant inhibition 
of lens browning as well as formation of advanced glyca-
tion end products suggesting that L-carnosine is worthy of 
further investigation as a promising prophylaxis for diabetic 
cataract.
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